|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Sebastian Werner||Member of Management Board & CFO||218,79k||N/D||N/D|
|Mr. Tilmann Bur||Member of Management Board & CEO||N/D||N/D||1965|
|Ralf Penner||Vice President of Investor Relations & Public Relations||N/D||N/D||N/D|
|Dr. Shaw Sorooshian||Senior Vice President of Medical Affairs||N/D||N/D||1964|
|Dr. Thomas Stoehr||Senior Vice President of Development||N/D||N/D||N/D|
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.
L'ISS Governance QualityScore di Paion AG al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.